We studied 29 patients on dialysis for terminal uremia, of whom one showed a dramatic rise in intraocular pressure (IOP) during dialysis. We examined the blood pressure (BP) and body weight (BW) before and after treatment in each patient and visual acuity by gonioscopic examination and optic disk status. After dialysis the statistically significant fall in BP and BW was observed in all patients, and in 28 subject an significant rise in IOP was noted. Only one patient experienced a dramatic rise in IOP, and he was the only one suffering from angular glaucoma during the last two years. All this time he was continually treated for glaucoma. After dialysis his IOP was 45 mmHg. With the adequate medication, his IOP lowered to the point when he was able to bear iridectomy which was done with argon and YAG laser. After the surgery his IOP reached the normal values. His visual acuity was good (1.0), visual field was normal, gonioscopic findings showed a narrow angle (Shaffer I, with normal pigmentation), and the optic disk had no abnormalities. It is not yet clear what was the cause of IOP rise during dialysis. It might be that the increased production of aqueous humor, which has been reported in such cases, might be caused by imbalance between blood and aqueous osmolality. If dialysis causes decrease in blood osmolality and if, at some time, blood becomes hypotonic in relation to ocular fluid, then the regular osmotic forces transfer the fluid to the ocular fluid into the eye. This case suggests that all patients on dialysis should undergo a minute ocular anamnesis and examination, and if needed administered adequate medication during the treatment.

Download full-text PDF

Source

Publication Analysis

Top Keywords

intraocular pressure
8
patients dialysis
8
dramatic rise
8
visual acuity
8
optic disk
8
rise iop
8
adequate medication
8
ocular fluid
8
dialysis
7
iop
7

Similar Publications

Treatment of pseudophakic aqueous misdirection syndrome.

Sci Rep

January 2025

Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse, 3010, Bern, Switzerland.

To describe the management and clinical course of 12 cases of pseudophakic aqueous misdirection syndrome (AMS). Twelve eyes of 12 Patients diagnosed with pseudophakic AMS between 2021 and 2022 were included. Best-corrected visual acuity, refraction, intraocular pressure (IOP), anti-glaucomatous medication, spectral domain ocular coherence tomography (SD-OCT) and postoperative complications were evaluated.

View Article and Find Full Text PDF

New treatments for glaucoma.

Curr Opin Ophthalmol

January 2025

New York Eye Surgery Center, New York City, New York, USA.

Purpose Of Review: This review highlights new Federal Drug Administration (FDA) approved glaucoma treatments to familiarize providers with immediately available options.

Recent Findings: New FDA-approved treatments include the bimatoprost implant, travoprost implant, direct selective laser trabeculoplasty (DSLT), and ocular pressure adjusting pump. The bimatoprost implant is approved for a single administration with effects lasting for about 1 year, as opposed to the nearly 3-year effect for the travoprost implant.

View Article and Find Full Text PDF

Glaucoma is an optic neuropathy in which progressive degeneration of retinal ganglion cells and the optic nerve leads to irreversible visual loss. Glaucoma is one of the leading causes of blindness. The pathogenesis of glaucoma is determined by different pathogenetic mechanisms, including increased intraocular pressure, mechanical stress, excitotoxicity, resistance to aqueous drainage and oxidative stress.

View Article and Find Full Text PDF

Background: The priority problem of modern healthcare is irreversible dementia due to the steady increase in morbidity. Among irreversible dementias, Alzheimer's disease takes the first place. Most often, only with sufficiently pronounced cognitive disorders, the doctor can diagnose Alzheimer's disease, although it is obvious that the neurodegenerative process begins even before the clinical manifestations of the disease.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Department of Ophthalmology, University of Washington, Seattle, WA, USA.

Background: To describe the settings and compare demographic and baseline clinical factors of the inaugural Eye Adult Changes in Thought (ACT) study participants.

Method: Adult Changes in Thought (ACT) is an ongoing cohort study of older adults (≥ 65 years) randomly recruited from Kaiser Permanente Washington who were cognitively normal at enrollment and followed biennially for the onset of Alzheimer's disease since 1994. Cognitive testing included the Cognitive Abilities Screening Instrument scored using Item Response Theory (CASI-IRT) with other measures of cognition.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!